Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background/Aim: Hepatic stellate cells (HSCs) express α-smooth muscle actin (αSMA) and acquire a profibrogenic phenotype upon activation by noxious stimuli. Insulin-like growth I (IGF-I) has been shown to stimulate HSCs proliferation in vitro, but it has been reported to reduce liver damage and fibrogenesis when given to cirrhotic rats. Methods: The authors used transgenic mice (SMP8-IGF-I) expressing IGF-I under control of αSMA promoter to study the influence of IGF-I synthesised by activated HSCs on the recovery from liver injury. Results: The transgene was expressed by HSCs from SMP8-IGF-I mice upon activation in culture and in the livers of these animals after CCl 4 challenge. Twenty four hours after administration of CCl 4 both transgenic and wild type mice showed similar extensive necrosis and increased levels of serum transaminases. However at 72 hours SMP8-IGF-I mice exhibited lower serum transaminases, reduced hepatic expression of αSMA, and improved liver morphology compared with wild type littermates. Remarkably, at this time all eight CCl 4 treated wild type mice manifested histological signs of liver necrosis that was severe in six of them, while six out of eight transgenic animals had virtually no necrosis. In SMP8-IGF-I mice robust DNA synthesis occurred earlier than in wild type animals and this was associated with enhanced production of HGF and lower TGFβ1 mRNA expression in the SMP8-IGF-I group. Moreover, Colα1(I) mRNA abundance at 72 hours was reduced in SMP8-IGF-I mice compared with wild type controls. Conclusions: Targeted overexpression of IGF-I by activated HSCs restricts their activation, attenuates fibrogenesis, and accelarates liver regeneration. These effects appear to be mediated in part by upregulation of HGF and downregulation of TGFβ1. The data indicate that IGF-I can modulate the cytokine response to liver injury facilitating regeneration and reducing fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Iredale, J. P., Benyon, R. C., Pickering, J., McCullen, M., Northrop, M., Pawley, S., Hovell, C., & Arthur, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1018 · Cited by 1,075
The role of TGFβ1 in initiating hepatic stellate cell activation in vivo
Hellerbrand, C., Stefanovic, B., Giordano, F., Burchardt, E. R., & Brenner, D. A. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80010-5 · Cited by 393
Self-citationShi, Z., Wakil, A. E., & Rockey, D. C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10663 · Cited by 310
Cited by
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Friedman, S. L. (2008) · Toxicology · doi:10.1016/j.tox.2008.06.013 · Cited by 350
IGF-1, inflammation and stem cells: interactions during muscle regeneration
MOURKIOTI, F., & ROSENTHAL, N. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.08.002 · Cited by 272
Pelosi, L., Giacinti, C., Nardis, C., Borsellino, G., Rizzuto, E., Nicoletti, C., Wannenes, F., Battistini, L., Rosenthal, N., Molinaro, M., et al. (2007) · The FASEB Journal · doi:10.1096/fj.06-7690com · Cited by 268
Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis
Mallat, A., & Lotersztajn, S. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00230.2013 · Cited by 211
“, hepatocyte growth factor, IGF-I, neurotrophins, interleukin-6, and Wnt ligands), which foster an environment favoring liver regeneration (6, 45, 68, 76, 86, 92).”
BackgroundThe role of growth hormone and insulin-like growth factor-I in the liver
Takahashi, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071447 · Cited by 193
IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner
Nishizawa, H., Iguchi, G., Fukuoka, H., Takahashi, M., Suda, K., Bando, H., Matsumoto, R., Yoshida, K., Odake, Y., Ogawa, W., et al. (2016) · Scientific Reports · doi:10.1038/srep34605 · Cited by 164
“These effects were associated with the antioxidant, antiapoptotic, antifibro-genic, and mitochondrial-protective effects of IGF-I 22,23 , although the precise mechanisms remain unclear.”
Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis
Zhao, W. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i10.1048 · Cited by 140
Markers of liver regeneration—the role of growth factors and cytokines: a systematic review
Hoffmann, K., Nagel, A. J., Tanabe, K., Fuchs, J., Dehlke, K., Ghamarnejad, O., Lemekhova, A., & Mehrabi, A. (2020) · BMC Surgery · doi:10.1186/s12893-019-0664-8 · Cited by 94
SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH
Luo, Y., Wadhawan, S., Greenfield, A., Decato, B. E., Oseini, A. M., Collen, R., Shevell, D. E., Thompson, J., Jarai, G., Charles, E. D., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1670 · Cited by 87
“IGF-1 has been reported in preclinical models to inactivate stellate cells and reduce fibrosis in the liver,(39) whereas IGFBP-1 and IGFBP-7 have been reported to promote fibrosis in preclinical models.”
Background
Metadata
- Authors
- Sanz, S., Pucilowska, J. B., Liu, S., Rodríguez-Ortigosa, C. M., Lund, P. K., Brenner, D. A., Fuller, C. R., Simmons, J. G., Pardo, A., Martínez-Chantar, M.-L., Fagin, J. A., & Prieto, J.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2004-12-10
- Volume
- 54
- Issue
- 1
- Pages
- 134-141
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2168752547
- Cited by
- 119
- References
- 3
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.